Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH

SOUTH SAN FRANCISCO, Calif., June 13, 2022 -- Akero Therapeutics, Inc. , a clinical-stage company developing transformational treatments for patients with serious metabolic diseases... | June 13, 2022

Related Keywords

Colorado ,United States ,Christina Tartaglia ,Tim Rolph ,Exchange Commission ,Company Phase ,Nasdaq ,Globenewswire Inc ,Keystone Symposium ,Tissue Fibrosis ,Human Disease ,Chief Scientific Officer ,South San ,Private Securities Litigation Reform Act ,Annual Report ,Akero Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Mouth ,Han ,Pune ,022 ,Ekero ,Company ,Developing ,Transformational ,Treatments ,Or ,Patients ,Ith ,Serious ,Etabolic Akro Us00973y1082 ,